4th Annual Highly Potent Active Pharmaceutical Ingredients conference 2020

SMi Group 11 - 12 May 2020, London, UK.
SMi is delighted to announce its 4th Annual Highly Potent Active Pharmaceutical Ingredients conference 2020 (HPAPI 2020) coming to London on the 11th - 12th May 2020. The conference focuses on the growing landscape driven by the demand for highly potent drugs in oncology, diabetes and autoimmune disease treatment.

HPAPI 2020 will address the biggest challenges the industry is facing with regards to determining toxicology limits, assessing hazards, implementing risk procures, translating risk assessment into facility engineering, preventing and dealing with cross-contamination and adhering to GMP regulatory guidelines.

Attend the conference and join our networking platform for industry professionals to provide you with the expertise to overcome the challenges of the HPAPI industry.

Network and learn from leading professionals such as:

Chair for 2020

  • Justin Mason-Home, Director, HPAPI Project Services Limited

Key speakers include

  • Pascal Michoux, Vice President, Global EHS Teva api & Biologics, teva API Italy
  • William Hawkins, Manager Occupation Toxicology, GsK
  • Brian Edwards, Chair, Pharmaceutical Human Factors Group, CIeHf
  • Thomas Adam, Head of GQA Chemical APIs, Bayer AG
  • Ildikó Ziegler, QA Manager, Gedeon Richter
  • Francois D’Hooge, ADC Project Manager, Gamamabs Pharma
  • Andreas Schreiner, Head of Validation, Novartis

Featured highlights

  • Explore HPAPI manufacturing with 8 big pharma from both the toxic substance and the employees’ perspective
  • Gain better understanding of human factors and ergonomics aspects and their role in improving production performance with the
  • Chartered Institute of Ergonomics and Human Factors
  • Deep dive into the oncology market and ADC production, the main driver of the HPAPI industry
  • Learn what it takes to create a safety company culture and how to better train your employees on risk perception

For further information and to register, please visit:
http://www.highlypotentapi.com/WPNEWs

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

73,000 Scientists collaborate over new COVID-19 Da…

More than 73,000 users collaborate on new online platform set up by the European Open Science Cloud Initiative, where scientists share COVID-19 data and accelerate our un...

Antiviral used to treat cat coronavirus also works…

Researchers at the University of Alberta are preparing to launch clinical trials of a drug used to cure a deadly disease caused by a coronavirus in cats that they expect ...

Search for COVID-19 drugs boosted by SARS discover…

An extensive search and testing of current drugs and drug-like compounds has revealed compounds previously developed to fight SARS might also work against COVID-19. Us...

Pfizer and BioNTech share positive early data on l…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) shared additional Phase 1 safety and immunogenicity data from their ongoing U.S. study of the BNT162 mRNA-based vac...

Phase I clinical trial initiated for monoclonal an…

The first participants have been dosed in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) in development for the prevention and treatment of...

Europe's largest initiative launches to accelerate…

CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launch to acceler...

Vitamin D deficiency may raise risk of getting COV…

In a retrospective study of patients tested for COVID-19, researchers at the University of Chicago Medicine found an association between vitamin D deficiency and the like...

Blocking cellular communication stops SARS-CoV-2

In the transmission of signals within the cell which, for example, stimulate cell growth or trigger metabolic processes, phosphate groups play an important biochemical ro...

Improving FDA's COVID-19 vaccine authorization and…

On March 28, the Food and Drug Administration (FDA) exercised its Emergency Use Authorization (EUA) authority to allow the use of hydroxychloroquine for the treatment of ...

Steroid found to improve survival of critically il…

A new international study published today has shown that treating critically ill patients with COVID-19 with the steroid hydrocortisone improves their chances of recovery...

Bayer and Informed Data Systems Inc. (One Drop) jo…

Bayer and Informed Data Systems Inc. (One Drop), a US-based digital health company, today announced that they have entered into an agreement to jointly develop digital he...

Abbott's fast, $5, 15-minute, easy-to-use COVID-19…

Abbott (NYSE: ABT) announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its BinaxNOW™ COVID-19 Ag Card rapid test f...